An Open-label Study to Evaluate the Pharmacokinetics and Safety of a Single Oral Dose of Alisporivir (DEB025) in Subjects With End Stage Renal Disease on Hemodialysis Compared to Matched Healthy Subjects

Trial Profile

An Open-label Study to Evaluate the Pharmacokinetics and Safety of a Single Oral Dose of Alisporivir (DEB025) in Subjects With End Stage Renal Disease on Hemodialysis Compared to Matched Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Aug 2016

At a glance

  • Drugs Alisporivir (Primary)
  • Indications Kidney disorders; Renal failure
  • Focus Pharmacokinetics
  • Sponsors Novartis
  • Most Recent Events

    • 16 Oct 2014 Status changed from recruiting to completed, according to the ClinicalTrials.gov record.
    • 29 May 2014 Planned End Date changed from 1 Dec 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.
    • 12 Nov 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top